United Therapeutics CEO Rothblatt sells $3.39m in shares

Martine Rothblatt, Chairperson and CEO of United Therapeutics (NASDAQ:UTHR), sold a total of $3.39 million in common stock on September 29 and 30. The sales, executed in multiple transactions, were priced between $416.3797 and $430.8125, near the stock’s 52-week high of $442.01. The $19 billion market cap company has shown impressive momentum, gaining over 36% in the past six months. InvestingPro analysis indicates the stock is currently trading close to its Fair Value.

On the same dates, Rothblatt exercised stock options to acquire 8,000 shares of United Therapeutics common stock at a price of $120.26, for a total value of $962,080.

These transactions were executed under a pre-arranged 10b5-1 trading plan adopted on May 2, 2025, set to continue until the earlier of December 31, 2025, or the exhaustion of a tranche of 294,000 stock options expiring March 15, 2026.

Following these transactions, Rothblatt directly owns 130 shares of United Therapeutics common stock. The stock currently trades at a P/E ratio of 16.65, reflecting the company’s strong market position. Additionally, Rothblatt indirectly holds shares through various family trusts. These include 166 shares held by spouse, 324,518 shares held in family trusts where the Reporting Person shares investment power, 258,117 shares held in family trusts where the Reporting Person’s spouse is sole trustee, 45,596 shares held in family trusts where the Reporting Person’s spouse shares investment power, and 15,962 shares held in family trusts where the Reporting Person is sole trustee. For comprehensive analysis and 12 additional ProTips on UTHR, visit InvestingPro.

In other recent news, United Therapeutics has been in the spotlight with a series of updates that are of interest to investors. UBS has raised its price target for United Therapeutics to $580, citing an optimistic outlook for Tyvaso, despite a slight reduction in revenue forecasts for the drug in 2025. Meanwhile, H.C. Wainwright has maintained its Buy rating and $500 price target, as the company deals with ongoing patent litigation involving Liquidia. TD Cowen has also reiterated a Buy rating with a $500 price target following the presentation of positive Phase III Tyvaso TETON-2 data in idiopathic pulmonary fibrosis patients, which drew significant attention at a recent conference.

Furthermore, RBC Capital has initiated coverage of United Therapeutics with an Outperform rating and a $569 price target, highlighting the company’s leadership in rare lung diseases. UBS continues to maintain a Buy rating with a $560 price target, emphasizing the potential $3-4 billion peak sales opportunity revealed by the IPF study results. These developments reflect a broad consensus among analysts on the promising future of United Therapeutics, as evidenced by the consistent Buy ratings and varied price targets.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.